The regulatory landscape for research peptides has shifted significantly heading into 2026, with FDA Category 1 classifications, compounding pharmacy restrictions, and policy signals from the Department of Health and Human Services reshaping how laboratories source and study these compounds. Understanding which peptides appear on the FDA-approved peptides list — and how Category 1 designations affect research access — is now essential knowledge for any serious investigator working in this space. This guide breaks down the current regulatory framework, highlights key compounds under scrutiny, and clarifies what these changes mean for preclinical research programs.
This article does not constitute legal or medical advice. The peptide regulatory environment is complex and evolving rapidly; researchers are encouraged to consult legal counsel and monitor official FDA communications for updates specific to their jurisdiction and institutional context.
Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied. All peptides discussed are referenced strictly in the context of preclinical and laboratory research.
Selank - 5MG — Research-Grade Reference Material Selank - 5MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
PT-141 - 10MG
$50.00$37.50 with 1st order
Ara-290 10MG
$45.00$33.75 with 1st order
Selank, Semax & P21 – 15MG
$90.00$67.50 with 1st order
Frequently Asked Questions
What does FDA Category 1 status mean for peptides?
FDA Category 1 is a classification used under the 503A and 503B compounding framework. Peptides placed in Category 1 are deemed inappropriate for compounding — meaning licensed compounding pharmacies cannot legally prepare them for prescriptive use. This designation does not automatically prohibit laboratory research use of these compounds, but it does restrict their clinical compounding pathway significantly.
Which peptides were placed on the FDA Category 1 list?
In late 2023 and into 2024–2025, the FDA finalized Category 1 placements for several widely studied peptides including BPC-157, TB-500 (Thymosin Beta-4 fragment), CJC-1295, Ipamorelin, Selank, Semax, Epithalon, and PT-141 (Bremelanotide), among others. PT-141 has a unique status as it is also the active ingredient in the FDA-approved drug Vyleesi, complicating its compounding pathway further.
What is the RFK peptide ban and does it affect researchers?
The term “RFK peptide ban” refers to policy directions emanating from HHS under Secretary Robert F. Kennedy Jr.’s tenure, which aligned with broader FDA enforcement of compounding restrictions on bioactive peptides. These actions targeted compounding pharmacies rather than research laboratories directly. However, the chilling effect on the broader peptide supply chain has prompted researchers to evaluate sourcing strategies carefully.
Are FDA-approved peptides the same as research-legal peptides?
Not necessarily. FDA-approved drugs (such as those containing semaglutide, bremelanotide, or oxytocin) have undergone clinical approval for specific indications. Research-grade peptides sold for laboratory purposes exist under a separate framework — they are not approved drugs, nor are they sold for human use. Their legality for research purposes differs by jurisdiction and institutional context.
Is BPC-157 banned by the FDA?
BPC-157 has been placed on the FDA’s Category 1 list, meaning it cannot be compounded by licensed compounding pharmacies for clinical use. It has not received FDA drug approval. However, it remains an active subject of preclinical and laboratory research globally. Researchers should review BPC-157’s FDA approval status in 2026 for a detailed breakdown of the regulatory nuances.
What peptides are still legally compoundable in 2026?
The compounding landscape changes frequently. As of available information, some peptides with established drug applications (such as oxytocin) retain more complex but navigable compounding pathways. Researchers and clinicians should consult the most current FDA 503A/503B nominee lists and seek legal guidance, as the list is actively updated.
Can research labs still purchase Category 1 peptides?
Research-grade peptides sold strictly for in vitro or preclinical laboratory use exist under a different regulatory category than compounded drugs. Many Category 1 peptides remain available for purchase by qualified research institutions and laboratories. Sourcing from reputable suppliers with clear research-only documentation is considered best practice.
What happened to semaglutide compounding in 2026?
Semaglutide (the active ingredient in Ozempic and Wegovy) was placed on the FDA shortage list, temporarily permitting compounding. As shortages resolved, the FDA moved to restrict compounding of semaglutide, triggering significant legal and policy debate. Researchers studying GLP-class peptides should monitor this situation closely, as it illustrates how shortage status directly influences compounding access.
Understanding the FDA Compounding Framework for Peptides
The FDA regulates peptides through multiple overlapping frameworks depending on their intended use: drug approval (NDA/BLA pathway), compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and research-use classifications. For the peptide research community, the most consequential recent developments involve the 503A/503B bulk substances lists — specifically, which compounds the FDA deems appropriate (Category 2) or inappropriate (Category 1) for compounding.
Selank - 5MG — Research-Grade Reference Material Selank - 5MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
PT-141 - 10MG
$50.00$37.50 with 1st order
Ara-290 10MG
$45.00$33.75 with 1st order
Selank, Semax & P21 – 15MG
$90.00$67.50 with 1st order
Category 1 effectively removes a peptide from the compounding pharmacy supply chain. Category 2 peptides may continue to be compounded subject to clinical justification. The Category 1/2 framework was originally intended to evaluate bulk drug substances nominated for compounding use, but its practical effect has been to create a de facto regulatory tiering system for bioactive peptides that many researchers now track carefully.
The Bulk Substances Nomination Process
Peptides enter the FDA’s bulk substances review through a nomination process. Once nominated, they are evaluated for safety, effectiveness evidence, and whether a clinical need exists that cannot be met by currently approved drugs. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) weighs in on Category determinations. Peptides placed in Category 1 are those where the FDA found insufficient evidence of clinical utility, raised safety concerns, or determined that an approved drug already meets the clinical need — as was the case with PT-141 and Vyleesi.
Key Peptides Affected by the 2024–2026 Regulatory Actions
BPC-157 and TB-500
Among the most discussed compounds in the Category 1 determinations, BPC-157 and TB-500 (a fragment of Thymosin Beta-4) have attracted substantial research attention for their roles in tissue repair and regeneration signaling pathways. Both peptides were placed in Category 1, restricting their compounding pathway. Preclinical research on these compounds continues globally, with investigators examining angiogenesis, tendon repair models, and gastrointestinal mucosal recovery. As the BPC-157 and TB-500 Wolverine Stack research guide outlines, these two peptides are frequently studied in combination for their potentially complementary mechanisms.
BPC-157 10MG Nasal Spray for research →
TB-500 10MG Nasal Spray for research →
CJC-1295 and Ipamorelin
Growth hormone secretagogue peptides including CJC-1295 and Ipamorelin were also swept into Category 1 designations. These compounds have been extensively studied in the context of GH pulse modulation, IGF-1 signaling, and metabolic research. As covered in our CJC-1295 with DAC vs. without DAC research comparison, the pharmacokinetic differences between formulations remain an active area of laboratory investigation regardless of compounding status.
Selank and Semax
Selank and Semax — both Russian-origin neuropeptides with nootropic and anxiolytic research profiles — were nominated and evaluated as bulk substances. Their Category 1 placement reflects the FDA’s position that insufficient evidence supports their compounding for clinical use in the U.S. market. Research into their BDNF-modulating and anxiolytic mechanisms continues in preclinical models, as summarized in the Selank and Semax blend research guide.
Selank & Semax Combination Nasal Spray for research →
PT-141 (Bremelanotide)
PT-141 occupies a unique regulatory position: it is simultaneously the active ingredient in the FDA-approved drug Vyleesi (approved for hypoactive sexual desire disorder in premenopausal women) and a subject of broader melanocortin receptor research. Its approved drug status actually strengthens the FDA’s basis for restricting its compounding — regulators argue the clinical need is already addressed. Laboratory research into its MC1R and MC4R binding properties and related signaling pathways remains active.
The GLP Peptide Regulatory Dimension
The GLP peptide class — encompassing semaglutide analogs, tirzepatide-related compounds, and investigational GLP-3 receptor agonists — represents perhaps the most watched regulatory frontier in 2026. Semaglutide compounding was temporarily permitted during FDA shortage declarations, but enforcement actions to restrict compounding began as manufacturers caught up with demand. This dynamic has driven significant interest in structurally distinct GLP-class research analogs.
Researchers studying satiety signaling, metabolic pathway modulation, and gut-brain axis communication continue to investigate GLP-class peptides extensively. The GLP-1 vs GLP-2 vs GLP-3 research comparison offers a mechanistic framework for understanding how these receptor classes differ in their downstream effects — relevant context for any research program tracking regulatory developments alongside the science.
GLP-1 (S) 10MG Nasal Spray for research →
What the Policy Signals from HHS Mean for Researchers
The phrase “RFK peptide ban” circulating in research and wellness communities conflates several distinct regulatory actions. What actually occurred was a confluence of: (1) FDA finalization of long-pending Category 1 determinations, (2) HHS-level policy emphasis on restricting what critics termed “unregulated” compounded biologics, and (3) enforcement letters to compounding pharmacies that had continued producing Category 1 peptides.
For research laboratories, the direct impact is primarily felt through supply chain disruption — as some domestic suppliers adjusted their offerings in response to the compounding restrictions. Research-grade peptide suppliers operating under a research-use framework rather than a compounding pharmacy model occupy a different regulatory space, though researchers should maintain up-to-date institutional compliance documentation regardless.
Institutional Compliance Considerations
- Researchers should verify that peptide purchases are accompanied by clear research-use documentation from suppliers
- Institutional Review Boards (IRBs) and IACUC committees should be consulted for any in vivo animal research protocols
- Legal counsel familiar with FDA regulatory frameworks is advisable for laboratories scaling up peptide research programs
- Sourcing from suppliers that provide certificates of analysis (CoA) and purity documentation remains best practice regardless of regulatory category
- Monitoring the FDA’s Compounding page and Federal Register notices provides the most current Category status updates
FDA-Approved Peptide Drugs: A Reference Overview
It is worth distinguishing research peptides from peptides that have received full FDA drug approval. Several peptide-based drugs have navigated the NDA/BLA pathway and hold approved status for specific indications. These include:
| Peptide/Drug | Active Peptide | Approved Indication | Research Status |
|---|---|---|---|
| Vyleesi | Bremelanotide (PT-141) | Hypoactive sexual desire disorder | Broader MC receptor research ongoing |
| Ozempic / Wegovy | Semaglutide | T2 diabetes / obesity | GLP-1 receptor agonist research active |
| Mounjaro / Zepbound | Tirzepatide | T2 diabetes / obesity | Dual GIP/GLP-1 receptor research |
| Natpara | Parathyroid hormone (1-84) | Hypoparathyroidism | Bone metabolism research |
| Lupron | Leuprolide (GnRH analog) | Prostate cancer, endometriosis | GnRH receptor signaling research |
| Forteo | Teriparatide (PTH 1-34) | Osteoporosis | Bone anabolic signaling studies |
This table illustrates that FDA drug approval is compound-specific and indication-specific — approval of bremelanotide in Vyleesi does not mean all PT-141 preparations are approved, just as approval of semaglutide in Ozempic does not extend to compounded semaglutide formulations.
Where These Fit in Your Research Library
Researchers building a comprehensive peptide research program will find the following resources and products relevant to the regulatory and scientific themes discussed in this guide:
- BPC-157 / TB-500 Wolverine Stack 20MG Nasal Spray → — For researchers studying the combined regenerative signaling mechanisms of two of the most discussed Category 1 peptides
- Ipamorelin 10MG Nasal Spray → — For GH secretagogue and pulsatile GH release research
- PT-141 10MG Nasal Spray → — For melanocortin receptor signaling investigations
Browse the full SourcePeptides research catalog for the complete range of research-grade compounds available with certificates of analysis.
Final Takeaway
The 2026 FDA-approved peptides landscape is defined by a tension between growing scientific interest in bioactive peptides and an increasingly structured regulatory framework governing their compounding and clinical use. The Category 1 designations for compounds like BPC-157, TB-500, CJC-1295, Ipamorelin, Selank, Semax, and others do not extinguish their research relevance — they restructure how researchers access and document their use. Understanding the distinction between FDA drug approval, compounding pharmacy status, and research-grade procurement is foundational for any laboratory operating in this space in 2026 and beyond.
Researchers are encouraged to monitor the FDA’s official communications, maintain rigorous institutional compliance documentation, and source peptides exclusively from suppliers with transparent quality and research-use frameworks. The science underlying these compounds continues to advance — navigating the regulatory environment carefully ensures that research programs can continue without interruption.
Sources & Further Reading
- FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Official FDA Resource)
- PubMed Search — BPC-157 Peptide Regeneration Research
- PubMed Search — Ipamorelin and Growth Hormone Secretagogue Studies
- Dhillon S. — “Bremelanotide: First Approval” — Drugs (2019)
- PubMed Search — Semaglutide GLP-1 Receptor Agonist Research
